NR4A1 and cancer: One hundred and seventy-eight patients had “Luminal B” tumors expressing both (50.4%) or one hormonal receptor/s (20.8%), whereas 72 (28.8%) showed “HER2-enriched” tumors i.e., both ER/PgR negative cancers.